search
Back to results

CGM and Lifestyle Changes in Patients With Impaired Glucose Tolerance

Primary Purpose

Impaired Glucose Tolerance

Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
CGM
Sponsored by
Nemours Children's Clinic
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Impaired Glucose Tolerance focused on measuring impaired glucose tolerance, obesity, adolescents

Eligibility Criteria

10 Years - 16 Years (Child)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Children 10 to <17 years old (i.e., before their 17th birthday)
  2. Impaired glucose tolerance based on standardized oral glucose tolerance test (OGTT) per American Diabetes Association criteria
  3. Overweight or obese (BMI ≥85th percentile for age/sex)
  4. Patients are pubertal, defined as females with breast Tanner stage II or above, or males with testicular volume ≥4 mL

Exclusion Criteria:

  1. Existing diagnosis of type 1 or type 2 diabetes
  2. Prepubertal
  3. Taking medications that affect insulin sensitivity (e.g., metformin, chronic corticosteroids whether systemic or inhaled)
  4. Patients and/or families not willing to wear the CGM for the duration of the study period or lack of compliance after recruitment

Sites / Locations

  • Nemours Children's ClinicRecruiting

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

CGM intervention

Arm Description

Continuous glucose monitoring with real-time glucose data using Dexcom G6.

Outcomes

Primary Outcome Measures

Insulin Sensitivity Score (ISS)
Change in insulin sensitivity as measured by insulin sensitivity Score (ISS). The ISS directly correlates with insulin sensitivity. Higher scores indicate higher insulin sensitivity; lower scores indicate more insulin resistance.

Secondary Outcome Measures

QUICKI insulin sensitivity
Change in insulin sensitivity as measured by QUICKI
QUICKI insulin sensitivity
Change in insulin sensitivity as measured by QUICKI
Insulin Sensitivity Score
Change in insulin sensitivity as measured by insulin sensitivity Score (ISS). The ISS directly correlates with insulin sensitivity. Higher scores indicate higher insulin sensitivity; lower scores indicate more insulin resistance.
Glycemic levels
Change in characteristics of glycemic levels obtained from the CGM data. This will include: mean, standard deviation of glucose levels time in range (glucose between 70-140 mg/dL) percent of time with hyperglycemia (>140 mg/dL) percent of time with hypoglycemia (<70 mg/dL)
Mean, standard deviation of sensor glucose levels
Change in characteristics of glycemic levels obtained from the CGM data, including mean and standard deviation of sensor glucose levels (mg/dL).
Time in range of sensor glucose levels
Change in glycemic levels obtained from the CGM data: Percent of time in range (glucose between 70-140 mg/dL)
Percent of sensor glucose levels in hypoglycemic range
Change in glycemic levels obtained from the CGM data: Percent of time with hypoglycemia (<70 mg/dL)
Percent of sensor glucose levels in hyperglycemic range
Change in glycemic levels obtained from the CGM data: Percent of time with hyperglycemia (>140 mg/dL)
Physical activity questionnaires
Questionnaires will be used to assess amount of time participants are active. Two questions regarding physical activity will be asked, with a scale set up as follows: How many minutes of continuous physical activity per week were completed? Possible answers will be <10, 11-20, 21-30, 31-60, 61-90, 91-120, or 121-150. How many days per week of physical activity longer than 30 minutes? Possible answers will be 0, 1, 2, 3, 4, 5, 6, or 7.
Dietary compliance questionnaires
Questionnaires will be used to assess particpants' compliance witih dietary changes. Four questions regarding their diet will be asked, with a scale set up as follows: How many sugary drinks per week? Possible answers will be 0, 1-2, 3-5, or >5. How many unhealthy snacks per week? Possible answers will be 0, 1-2, 3-5, or >5. How many times junk food was consume in the past week? Possible answers will be 0, 1-2, 3-5, or >5. How often were the proper portion sizes followed (as per control plate)? Possible answers will be always, most days, occasionally, or never.

Full Information

First Posted
May 16, 2022
Last Updated
April 13, 2023
Sponsor
Nemours Children's Clinic
search

1. Study Identification

Unique Protocol Identification Number
NCT05387551
Brief Title
CGM and Lifestyle Changes in Patients With Impaired Glucose Tolerance
Official Title
Effect of Adding Continuous Glucose Monitoring (CGM) to Lifestyle Changes on Insulin Sensitivity in Patients With Impaired Glucose Tolerance
Study Type
Interventional

2. Study Status

Record Verification Date
April 2023
Overall Recruitment Status
Recruiting
Study Start Date
December 1, 2022 (Actual)
Primary Completion Date
June 2024 (Anticipated)
Study Completion Date
June 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Nemours Children's Clinic

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
No

5. Study Description

Brief Summary
The incidence of type 2 diabetes (T2D) in children is increasing, paralleling the rising incidence of obesity. Preventing children and adolescents from developing T2D is critical. The health benefits of lifestyle modifications are well documented in this population, but success rates are low. Obesity in children and adolescents increases the risk of not only T2D but other complications as well, such as hypertension, dyslipidemias and more. The investigators hypothesize that having real-time glucose data with the use of a continuous glucose monitor (CGM) in obese patients with impaired glucose tolerance will improve adherence to lifestyle modifications. As a result, a decrease in body mass index (BMI) is expected with subsequent improvement in insulin sensitivity, thus reducing risk of obesity-related complications later in childhood/adolescence and adulthood.
Detailed Description
The purpose of this research is to evaluate if having blood sugar information from a continuous glucose monitor (CGM) during activities of daily living provides additional benefit to lifestyle modifications in reducing the risk of developing diabetes and achieving a healthier weight. A CGM is a small device often worn on the back of the arm that uses a very small needle to insert a small sensor just under the skin in the fatty tissue. The CGM device transmits the blood sugar level to either a smartphone or a special receiver. The investigators expect patients will have an overall improvement in health by decreasing weight and therefore improving the way the child's insulin works in their body. This could result in decreased risk of obesity-related complications such as diabetes mellitus, cardiovascular disease, kidney disease, and loss of vision and/or limbs, among others.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Impaired Glucose Tolerance
Keywords
impaired glucose tolerance, obesity, adolescents

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
15 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
CGM intervention
Arm Type
Experimental
Arm Description
Continuous glucose monitoring with real-time glucose data using Dexcom G6.
Intervention Type
Device
Intervention Name(s)
CGM
Other Intervention Name(s)
Dexcom G6
Intervention Description
Dexcom G6 sensor, transmitter and supplies will be provided to family for use. Participants will wear G6 and have real-time glucose data throughout the study.
Primary Outcome Measure Information:
Title
Insulin Sensitivity Score (ISS)
Description
Change in insulin sensitivity as measured by insulin sensitivity Score (ISS). The ISS directly correlates with insulin sensitivity. Higher scores indicate higher insulin sensitivity; lower scores indicate more insulin resistance.
Time Frame
Baseline to 6 months
Secondary Outcome Measure Information:
Title
QUICKI insulin sensitivity
Description
Change in insulin sensitivity as measured by QUICKI
Time Frame
Baseline to 3 months
Title
QUICKI insulin sensitivity
Description
Change in insulin sensitivity as measured by QUICKI
Time Frame
Baseline to 6 months
Title
Insulin Sensitivity Score
Description
Change in insulin sensitivity as measured by insulin sensitivity Score (ISS). The ISS directly correlates with insulin sensitivity. Higher scores indicate higher insulin sensitivity; lower scores indicate more insulin resistance.
Time Frame
Baseline to 3 months
Title
Glycemic levels
Description
Change in characteristics of glycemic levels obtained from the CGM data. This will include: mean, standard deviation of glucose levels time in range (glucose between 70-140 mg/dL) percent of time with hyperglycemia (>140 mg/dL) percent of time with hypoglycemia (<70 mg/dL)
Time Frame
Baseline to 3 and 6 months
Title
Mean, standard deviation of sensor glucose levels
Description
Change in characteristics of glycemic levels obtained from the CGM data, including mean and standard deviation of sensor glucose levels (mg/dL).
Time Frame
Baseline to 3 and 6 months
Title
Time in range of sensor glucose levels
Description
Change in glycemic levels obtained from the CGM data: Percent of time in range (glucose between 70-140 mg/dL)
Time Frame
Baseline to 3 and 6 months
Title
Percent of sensor glucose levels in hypoglycemic range
Description
Change in glycemic levels obtained from the CGM data: Percent of time with hypoglycemia (<70 mg/dL)
Time Frame
Baseline to 3 and 6 months
Title
Percent of sensor glucose levels in hyperglycemic range
Description
Change in glycemic levels obtained from the CGM data: Percent of time with hyperglycemia (>140 mg/dL)
Time Frame
Baseline to 3 and 6 months
Title
Physical activity questionnaires
Description
Questionnaires will be used to assess amount of time participants are active. Two questions regarding physical activity will be asked, with a scale set up as follows: How many minutes of continuous physical activity per week were completed? Possible answers will be <10, 11-20, 21-30, 31-60, 61-90, 91-120, or 121-150. How many days per week of physical activity longer than 30 minutes? Possible answers will be 0, 1, 2, 3, 4, 5, 6, or 7.
Time Frame
3 and 6 months
Title
Dietary compliance questionnaires
Description
Questionnaires will be used to assess particpants' compliance witih dietary changes. Four questions regarding their diet will be asked, with a scale set up as follows: How many sugary drinks per week? Possible answers will be 0, 1-2, 3-5, or >5. How many unhealthy snacks per week? Possible answers will be 0, 1-2, 3-5, or >5. How many times junk food was consume in the past week? Possible answers will be 0, 1-2, 3-5, or >5. How often were the proper portion sizes followed (as per control plate)? Possible answers will be always, most days, occasionally, or never.
Time Frame
3 and 6 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
10 Years
Maximum Age & Unit of Time
16 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Children 10 to <17 years old (i.e., before their 17th birthday) Impaired glucose tolerance based on standardized oral glucose tolerance test (OGTT) per American Diabetes Association criteria Overweight or obese (BMI ≥85th percentile for age/sex) Patients are pubertal, defined as females with breast Tanner stage II or above, or males with testicular volume ≥4 mL Exclusion Criteria: Existing diagnosis of type 1 or type 2 diabetes Prepubertal Taking medications that affect insulin sensitivity (e.g., metformin, chronic corticosteroids whether systemic or inhaled) Patients and/or families not willing to wear the CGM for the duration of the study period or lack of compliance after recruitment
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Larry Fox, MD
Phone
9046973674
Email
larry.fox@nemours.org
First Name & Middle Initial & Last Name or Official Title & Degree
Leo Maldonado, MD
Phone
9046974674
Email
Leopoldo.Maldonado@nemours.org
Facility Information:
Facility Name
Nemours Children's Clinic
City
Jacksonville
State/Province
Florida
ZIP/Postal Code
32207
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Leo Maldonado, MD
Phone
904-697-3600
First Name & Middle Initial & Last Name & Degree
Larry A Fox, MD

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

CGM and Lifestyle Changes in Patients With Impaired Glucose Tolerance

We'll reach out to this number within 24 hrs